英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
broce查看　broce　在百度字典中的解释百度英翻中〔查看〕
broce查看　broce　在Google字典中的解释Google英翻中〔查看〕
broce查看　broce　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Almirall receives European Commission approval of EBGLYSS . . .
    Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity, selectively inhibiting its downstream signallingi,ii,iii,iv Following the European Commission approval, Germany is the first country where lebrikizumab will be available for prescription Lebrikizumab demonstrated early clinical efficacy and maintenance of response up to 2 years in both monotherapy and combination
  • EBGLYSS® (lebrikizumab) is ranked as number one of the interleukin . . .
    Norway is the first country in the Nordic region where lebrikizumab will be available as a prescription medicine Lebrikizumab (EBGLYSS) is ranked as the number one interleukin inhibitor for severe atopic dermatitis (AD) in adults and adolescents on TNF BIO 2406b from May 1, 2024 1,2
  • Healthcare professionals | Almirall
    Our close partnership with patients and dermatologists makes us a trusted and reliable partner to them
  • EBGLYSS® (lebrikizumab) receives positive CHMP opinion for . . . - Almirall
    We are confident that EBGLYSS, thanks to its selective mechanism of action, proven long-term efficacy and patient friendly monthly maintenance dosing has the potential to become a first-line treatment for moderate-to-severe atopic dermatitis " said Karl Ziegelbauer, Chief Scientific Officer at Almirall
  • Almirall’s H1 2024 Results
    Biologics continue to be key growth engines for Almirall: Ebglyss® launch gaining traction in Germany (€11 MM Net Sales YTD) with increasing dynamic market share as well as recent launches in Norway and the UK Ilumetri® showing 25% increase in sales vs H1 2023 (total of €100 5 MM in H1)
  • Almirall announces “LumiNE”, a phase III clinical study assessing the . . .
    Barcelona 15th January 2026 - Almirall, S A (ALM), a global pharmaceutical company dedicated to medical dermatology, announces the planned start of a phase III study assessing the efficacy and safety of Lebrikizumab (Ebglyss®), currently approved for the treatment of moderate-to-severe atopic dermatitis) in patients with nummular eczema
  • Almirall delivers a strong start to 2025: growing Q1 overall sales by . . .
    Continued strong growth trajectory with 15% Net Sales increase to a total of €284 6 MM with key products delivering high double-digit YoY growth and general medicines business aided by Q1 2025 out-licensing transaction EBITDA increase of 35 0% YoY in line with expectations to a total of €70 9 MM driven by continued strong operational execution including out-licensing income realized in Q1
  • Almirall: Nearly 80% of patients with moderate-to-severe atopic . . .
    BARCELONA, Spain 20th October, 2023 - Almirall S A (BME:ALM), a global biopharmaceutical company focused on medical dermatology, today announced results from the long-term extension study ADjoin which showed patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and
  • AAD 2026: Almirall presents new clinical and real‑world evidence across . . .
    Almirall advances scientific leadership in medical dermatology with new data across atopic dermatitis, psoriasis, actinic keratosis and acne, reinforcing its commitment to improving patient outcomes More than 15 posters will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, including 9 on lebrikizumab, new analyses for tirbanibulin, two on tildrakizumab showing
  • Almirall at the JPMorgan Conference - entering a new era of sustained . . .
    Almirall's unique dedication to medical dermatology and innovation - combined with its commercial excellence - fuel an era of sustained double-digit growth (net sales CAGR 2023- 2030) and profitability enabling the company to reach more patients with relevant and impactful products Growth of Almirall’s psoriasis and atopic dermatitis franchises is anticipated to lead to over 800 million in





中文字典-英文字典  2005-2009